NCT05054257

Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients with Relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. a Dose Escalation, Open-label, Phase I Study.

Study Summary

Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.

Want to learn more about this trial?

Request More Info

Autologous CAR19 T lymphocytesDRUG

First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL

Facility	City	State	Country
Institute of Hematology and Blood Transfusion, Czech Republic	Prague		Czechia

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026